Department of Radiotherapy, ICANS, Institut Cancérologie Strasbourg Europe, 17 Rue Albert Calmette, 67200, Strasbourg Cedex, France.
Département of Pathology, Hautepierre University Hospital, 1, Avenue Molière, 67200, Strasbourg, France.
Crit Rev Oncol Hematol. 2021 Jan;157:103188. doi: 10.1016/j.critrevonc.2020.103188. Epub 2020 Dec 8.
With new therapeutic protocols, more patients treated for glioblastoma have experienced a suspicious radiologic image of progression (pseudoprogression) during follow-up. Pseudoprogression should be differentiated from true progression because the disease management is completely different. In the case of pseudoprogression, the follow-up continues, and the patient is considered stable. In the case of true progression, a treatment adjustment is necessary. Presently, a pseudoprogression diagnosis certainly needs to be pathologically confirmed. Some important efforts in the radiological, histopathological, and genomic fields have been made to differentiate pseudoprogression from true progression, and the assessment of response criteria exists but remains limited. The aim of this paper is to highlight clinical and pathological markers to differentiate pseudoprogression from true progression through a literature review.
随着新的治疗方案的出现，更多接受胶质母细胞瘤治疗的患者在随访中经历了可疑的影像学进展（假性进展）。假性进展需要与真正的进展区分开来，因为疾病的管理是完全不同的。在假性进展的情况下，随访继续进行，患者被认为是稳定的。在真正的进展的情况下，需要调整治疗。目前，假性进展的诊断肯定需要病理证实。在影像学、组织病理学和基因组学领域已经做出了一些重要的努力来区分假性进展和真正的进展，并且存在但仍然有限的评估反应标准。本文的目的是通过文献回顾，强调临床和病理标志物，以区分假性进展和真正的进展。
